NASDAQ, ZIOP - Ziopharm Oncology IN
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to
develop and commercialize a diverse, risk-sensitive portfolio of in-licensed
cancer drugs that address unmet medical needs. Our principal focus is on the
licensing and development of proprietary drug candidates that are related to
cancer therapeutics already on the market or in development and that can be
developed in intravenous (?IV?) and/or oral forms of administration. We believe
this strategy will result in lower risk and expedited drug development programs.
While we expect to commercialize our products on our own in North America, we
also recognize that promising clinical trial results might also be addressed in
partnership with another company with the requisite financial resources.
Currently, we are in phase I and/or II studies for three product candidates
identified as darinaparsin (?ZIO-101?), palifosfamide (?ZIO-201?), and indibulin
(?ZIO-301?). ...
Read SEC Filing on NASDAQ.com »